Impact of facility type and volume on survival in patients with metastatic renal cell carcinoma

Furkan Dursun, Ahmed Elshabrawy, Hanzhang Wang, James Oelsen, Michael A Liss, Dharam Kaushik, Chethan Ramamurthy, Ronald Rodriguez, Ahmed M Mansour Elkenany

Producción científica: Articlerevisión exhaustiva

1 Cita (Scopus)

Resumen

INTRODUCTION: To investigate the impact of facility type and volume on survival in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: We investigated the National Cancer Database for patients with mRCC. Patients were stratified according to treatment facility type (academic vs. non-academic) and facility volume (high, intermediate, and low). Kaplan-Meier survival estimates and Cox proportional hazard models were fitted to evaluate overall survival (OS) as a function of facility type, volume, and different treatment modalities. RESULTS: A total of 27,598 patients were identified, of which 10,938 (40%) were treated at academic centers (AC) and 16,131 (60%) at non-academic centers (non-AC). Overall, 19,904 patients (72%) were treated in high-volume hospitals (HVH). Among patients treated at AC, 94% were treated at HVHs. Patients treated at AC were more likely to receive immunotherapy, undergo cytoreductive nephrectomy (CN) and metastasectomy. The 2 and 5 year OS rates for patients treated in AC were 29.7% (CI 28.8%-30.6%) and 13% (CI 12%-14%) vs. 21.7% (CI 21%-22.4%) and 8.4% (CI %7.91-%8.99) in the Non-AC, respectively (p < 0.001). Multivariate Cox regression analysis identified treatment at AC as an independent predictor of survival (HR 0.85, 95% CI 0.81-0.91, p < 0.001). Undergoing CN and receipt of immunotherapy was also associated with a survival benefit (HR 0.41, CI 0.40-0.43 and HR 0.63, CI 0.59-0.68 respectively, p < 0.001). CONCLUSIONS: Treatment at ACs and HVHs was associated with a survival benefit in patients with mRCC. Patients treated at AC were more likely to receive immunotherapy, undergo CN and metastasectomy.

Idioma originalEnglish (US)
Páginas (desde-hasta)10806-10816
Número de páginas11
PublicaciónThe Canadian journal of urology
Volumen28
N.º5
EstadoPublished - oct 1 2021

ASJC Scopus subject areas

  • Urology

Huella

Profundice en los temas de investigación de 'Impact of facility type and volume on survival in patients with metastatic renal cell carcinoma'. En conjunto forman una huella única.

Citar esto